Showing 41-50 of 128 results for "".
- Aquavit Files Additional IND for New Toxin for Palmar Hyperhidrosishttps://practicaldermatology.com/news/aquavit-files-additional-ind-for-new-toxin-for-palmar-hyperhidrosis/2461625/Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived from neurotoxins produce…
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orlean…
- Mount Sinai Researchers Awarded $12 Million NIH Grant to Create a Center to Study Causes of Atopic Dermatitis and Food Allergyhttps://practicaldermatology.com/news/mount-sinai-researchers-awarded-12-million-nih-grant-to-create-a-center-to-study-causes-of-atopic-dermatitis-and-food-allergy/2461520/Mount Sinai researchers have been awarded $12 million over 5 years by the National Institutes of Health (NIH) to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis, according to a news release. The Systems Biology of Early Atopy (SunBEAm…
- AAD Issues Updated Guidelines for the Management of Atopic Dermatitis in Adults with Topical Therapieshttps://practicaldermatology.com/news/aad-issues-updated-guidelines-for-the-management-of-atopic-dermatitis-in-adults-with-topical-therapies/2461499/The American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy of Dermatology. This is the second in a series of updated guidelines the AAD is producing on the conditi…
- Practical Dermatology® Magazine’s Sister Publication Named Exclusive Media Partner for Octane’s Aesthetics Tech Forum 2023https://practicaldermatology.com/news/practical-dermatology-magazines-sister-publication-named-exclusive-media-partner-for-octanes-aesthetics-tech-forum-2023/2461474/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is the exclusive media partner for Octane’s Aesthetics Tech Forum 2023.Now in its fourth year, Octane's Aesthetics Tech Forum is a two-day immersive, in-person and digital experience that brings together leading physicians, in…
- DefenAge Scores Defensin Master Anti-Aging Patenthttps://practicaldermatology.com/news/defenage-scores-defensin-master-anti-aging-patent/2461443/DefenAge Skincare received Defensin Master Anti-Aging Patent from the US Patent Office (Patent #11,491,096). The new patent recognizes DefenAge's ground-breaking cell stimulating compositions and methods to create fresh, new skin. This patent concludes the international family of DefenAge's patent…
- Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in PsA, Non-Radiographic Axial Spondyloarthritis, and AShttps://practicaldermatology.com/news/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psa-non-radiographic-axial-spondyloarthritis-and-as/2461422/Bimekizumab demonstrated sustained clinical responses to Week 52 in Phase 3 studies in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.. The findings were presented at the ACR Convergence 2022 in Philadelphia, November 10–14, 2022. In BE OPTIMAL, clinical …
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when selecting a treatment option for adoles…
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recomme…
- Lilly's Taltz Now Available in Citrate-Free Formulationhttps://practicaldermatology.com/news/lillys-taltz-now-available-in-citrate-free-formulation/2461291/Lilly's Taltz® (ixekizumab) is now available in a new, citrate-free formulation to reduce injection site pain. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formulation. The new Taltz form…